

10 September 2021



Dear Valued Shareholders,

**RE: MINUTES OF THE MEETING OF MEMBERS OF DUOPHARMA BIOTECH BERHAD  
HELD ON FRIDAY, 13 AUGUST 2021**

Duopharma Biotech Berhad (the "Company") is pleased to inform that Minutes of the Meeting of Members of the Company held on Friday, 13 August 2021 ("MOM") have been published on our website at the Investor Relations section. The Minutes have incorporated the following:

- (i) the summary of the key matters discussed at the MOM;
- (ii) the pre-MOM Questions received from Shareholders and the answers thereto; and
- (iii) the Questions received from Shareholders or their Proxies/Corporate Representatives during the MOM and the answers thereto.

Thank you.

Yours faithfully  
for and on behalf of

**DUOPHARMA BIOTECH BERHAD**



**LEONARD ARIFF BIN ABDUL SHATAR**  
Group Managing Director

**DUOPHARMA BIOTECH BERHAD**

Registration No: 200001021664 (524271-W)

Suite 18.06, Level 18, Kenanga International, No. 26, Jalan Sultan Ismail, 50250 Kuala Lumpur, Malaysia.  
General line +603 2162 0218 Fax +603 2161 0507 [www.duopharmabiotech.com](http://www.duopharmabiotech.com)



CERTIFIED TO ISO 37001:2016  
CERT. NO.: ACRMS 00168

**DUOPHARMA BIOTECH BERHAD**  
Registration No.: 200001021664 (524271-W)  
Incorporated in Malaysia

**MINUTES OF THE MEETING OF MEMBERS ("MOM") OF DUOPHARMA BIOTECH BERHAD ("DUOPHARMA" OR THE "COMPANY") HELD FULLY VIRTUAL THROUGH LIVE STREAMING AND ONLINE REMOTE VOTING USING REMOTE PARTICIPATION AND VOTING ("RPV") FACILITIES VIA THE TIIH ONLINE MEETING PLATFORM PROVIDED BY TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHD IN MALAYSIA AT <https://tiih.online> ON FRIDAY, 13 AUGUST 2021 AT 9.00 A.M.**

---

**DIRECTORS' PRESENT**

**VIRTUALLY VIA ZOOM  
PLATFORM**

- : YBhg. Tan Sri Datin Paduka Siti Sa'diah binti Sh Bakir  
– Non-Independent Non-Executive Chairman  
(Also as Proxy) (the "Chairman")  
Encik Leonard Ariff bin Abdul Shatar  
– Group Managing Director  
YBhg. Dato' Mohamad Kamarudin bin Hassan  
– Senior Independent Non-Executive Director  
Encik Razalee bin Amin  
– Independent Non-Executive Director  
Puan Zaiton binti Jamaluddin  
– Independent Non-Executive Director  
YBhg. Dato' Eisah binti A. Rahman  
– Independent Non-Executive Director  
YBhg. Datuk Nik Moustpha bin Hj Nik Hassan  
– Independent Non-Executive Director  
YBhg. Datuk Mohd Radzif bin Mohd Yunus  
– Non-Independent Non-Executive Director  
YBhg. Dato' Dr Zaki Morad bin Mohamad Zaher  
– Independent Non-Executive Director  
Puan Amizar Binti Mizuar  
– Non-Independent Non-Executive Director

**COMPANY SECRETARY**

**PRESENT VIRTUALLY**

**VIA ZOOM PLATFORM**

- : Encik Ibrahim Hussin Salleh  
– Company Secretary

**SENIOR MANAGEMENT  
PRESENT VIRTUALLY  
VIA ZOOM PLATFORM**

- : Encik Wan-Amir Jeffery Bin Wan Abdul Majid  
– Chief Operating Officer (Question & Answer Moderator)  
Mr Chek Wu Kong  
– Chief Financial Officer  
Encik Shamsul Idham bin A.Iahad  
– Chief Executive Officer, Duopharma Consumer  
Healthcare Sdn. Bhd.

**SENIOR MANAGEMENT  
PRESENT VIA TIIH  
ONLINE**

- : Mr Krisnakumara-Reddi A/L Kesava-Reddi  
– Chief Manufacturing Officer  
Ms Ng Su Yee  
– Chief Technical Officer

**OTHERS VIA ZOOM  
PLATFORM**

- : Mr Rama Sockalingam a/l Nagappan  
– Group Internal Audit (Observer)  
Puan Fatimah Binti Fadzil  
– Manager, Company Secretarial  
Cik Shazrin Erma Binti Azmi  
– Assistant Manager, Company Secretary (Question & Answer Moderator)  
Puan Soleha Binti Ab Shukor  
– Manager I, Corporate Communication (Question & Answer Moderator)  
Mr Kelvin Gan Rion  
– Executive, Finance (Question & Answer Moderator)  
Encik Ameenuddin Bin Khali Kasman  
– Partner of KPMG PLT (External Auditors)  
Mr Chris Lai  
– Associate Director of Mercury Securities Sdn. Bhd. (Principal Adviser for the Proposed Bonus Issue)  
Mr Lim Wee Chien  
– Partner from Wee Chien & Partners (Legal Adviser for the Proposed Bonus Issue)  
Puan Suzana binti Abdul Rahim  
– Tricor Investor & Issuing House Services Sdn Bhd (Share Registrar and Poll Administrator)  
Cik Nur Qaisara Naalla @ Nella Nyoyew  
– Tricor Investor & Issuing House Services Sdn Bhd (Share Registrar and Poll Administrator)

**OTHERS VIA ZOOM  
PLATFORM**

- : Ms Melissa Liew  
- Scrutineer Solutions Sdn. Bhd. (Scrutineers)  
Meor Ahmad Sufian B. Meor Mohamed Albakri  
– Tricor Investor & Issuing House Services Sdn Bhd (Audio  
visual technician)  
Ahmad Rifai B. Nasir  
– Tricor Investor & Issuing House Services Sdn Bhd (Audio  
visual technician)

The above attendees were as listed in Annexure I of the Minutes of the MOM of Duopharma Biotech Berhad (the "MOM" or the "Meeting").

The attendance of Members/Corporate Representatives/Proxies was as per Summary of Attendance List by way of Remote Participation and Voting ("RPV") at TIH Online in Annexure II of the Minutes of the Meeting.

**QUORUM**

According to Article 69 of the Company's Constitution, the quorum for the meeting shall be two (2) members present in person. A 'member' includes a proxy and a corporate representative, according to Article 69, 82 and 83(3)(a) and 90 of the Company's Constitution, respectively.

As the number of members present was sufficient, the Secretary confirmed that a quorum was present and the Notice of the Meeting of Members of the Company was taken as read. The Company had received 120 valid proxies totalling 478,326,536 shares representing 52.99% of the Company's Issued and Paid-up share capital.

In addition to this, based on the registration data given by the Company's Share Registrar as at 9.00 a.m. on 13 August 2021, there were 66 shareholders that had registered through the Remote Participation and Voting ("RPV") facility for attendance at the Meeting, representing 430,247,509 ordinary shares which constituted 60.91% of the total issued shares of the Company.

**NOTICE OF MEETING**

The notice convening the Meeting dated 6 July 2021 was tabled and taken as read.

The Chairman informed that the Company had also issued to shareholders an Administrative Guide setting out guidelines on joining and participating in the Meeting of Members via RPV.

**CHAIRMAN'S OPENING REMARKS**

The Chairman welcomed all members to the Meeting of Members of the Company.

The Chairman highlighted that the global Covid-19 pandemic was still ongoing and as a continuation of efforts to break the chain of the infection, the Government has implemented the Movement Control Order or 'MCO' nationwide. The current phase of the MCO would continue until 31 December 2021. As the number of new positive cases was still very high, the shareholders were urged to support the National Covid-19 Immunisation Programme and get vaccinated against the Covid-19 virus to help Malaysia achieve herd immunity and break the chain of infection.

In relation thereto, the Board of Directors of the Company had decided that the Meeting of Members be conducted fully virtual where all meeting participants including the Chairman of the meeting, board members, senior management and shareholders participate in the meeting online, in line with the latest guidance for conducting a fully virtual meeting as issued by the Securities Commission Malaysia.

The Chairman informed that pursuant to the SC Guidance and Section 327(2) of the Companies Act 2016, the Chairman shall be present at the main venue of the Meeting to chair the Meeting and that the main venue of the Meeting was the online platform used to conduct the Meeting. Further, should the Chairman be unable to continue to chair the meeting due to internet connection being unstable, disconnected or for any other reason, the Senior Independent Director, YBhg. Dato' Mohamad Kamarudin, and failing him, Independent Director, Encik Razalee, would take over the Chair of the meeting.

The Chairman introduced the Board Members, the Members of the Senior Management and essential individuals who were present virtually via online platform.

#### **GENERAL INSTRUCTIONS ON MEETING PROCEDURES**

The Company Secretary briefed the shareholders, corporate representatives and proxies present virtually at the Meeting of their right to ask questions and vote on the resolutions in the agenda of the Meeting. He informed that pursuant to Paragraph 8.29A(1) of the Bursa Malaysia Listing Requirements, all resolutions in the Notice of Meeting of Members which were put to vote shall be decided on a poll and that every member present in person or by proxy shall have one (1) vote for each share he/ she holds.

The Company had appointed Tricor Investor & Issuing House Services Sdn Bhd ("Tricor") as the Poll Administrator to conduct the poll for the Meeting, and appointed Scrutineer Solutions Sdn.Bhd. as the scrutineers to verify the poll results. To allay concerns by shareholders that companies may selectively avail and respond to questions in a virtual general meeting environment, the Company had assembled a team of moderators comprising representatives from Senior Management, company secretary's office, finance and corporate communication to objectively stream the questions raised by shareholders during the virtual Meeting. The Company's Group Internal Auditor would provide oversight to ensure all questions have been objectively selected and streamed.

The Board members and the Senior Management of the Company were present to answer any questions from members on the matters set out in the agenda for the MOM.

The shareholders were to use the Query Box, as the primary mode of communication via TIH online, to raise question(s) during the virtual MOM and the Company would endeavour to respond to all questions posed during the virtual MOM. The Company would respond to all relevant unanswered questions via the website within one (1) month from the virtual MOM date. A short video presentation on the demonstration of the online e-voting process was broadcasted by Tricor, the Company's Poll Administrator. The voting session had commenced from the start of the Meeting at 9.00 a.m..

Before the meeting proceeded to the agenda proper, The Chairman briefed the shareholders, corporate representatives and proxies present virtually at the Meeting on the conduct of each agenda item for the Meeting.

As for the shareholders who had appointed Tan Sri Chairman as their proxy, the Chairman, shall vote in accordance to the shareholders' instructions.

With respect to the submission of questions for this MOM, the Company had allowed shareholders to submit their questions online prior to the meeting and the Company had received a number of questions. The Chairman further informed that the shareholders could still continue to submit their questions online using the TIH Online Query Box facility during the Meeting. The Group Managing Director and the Management team would be invited to assist the Board in responding to the questions received prior to as well as during the MOM.

#### **AGENDA NO. 1 (ORDINARY RESOLUTION)**

**Proposed Bonus Issue of 235,443,397 New Ordinary Shares in Duopharma Biotech Berhad ("Duopharma") ("Duopharma Shares") ("Bonus Shares") on the basis of 1 bonus share for every 3 existing Duopharma Shares held on an entitlement date to be determined and announced later ("Proposed Bonus Issue")**

The Chairman tabled the following Ordinary Resolution: -

**"THAT** subject to the approvals of all relevant regulatory authorities for the listing of and quotation for 235,443,397 Bonus Shares on the Main Market of Bursa Malaysia Securities Berhad, the Board of Directors of Duopharma ("**Board**") be and is hereby authorised to issue 235,443,397 Bonus Shares on the basis of 1 Bonus Share for every 3 existing Duopharma Shares held by shareholders of Duopharma whose names appear in the Company's Record of Depositors as at 5:00 p.m. on an entitlement date to be determined and announced later by the Board;

**THAT** the Bonus Shares shall, upon allotment and issuance, rank *pari passu* in all respects with the then existing Duopharma Shares, save and except that the Bonus Shares will not be entitled to any dividends, rights, allotments and/or other distributions that may be declared, made or paid, the entitlement date of which is prior to the date of allotment and issuance of the Bonus Shares;

**AND THAT** the Board be and is hereby authorised to take all such necessary steps to give effect to the Proposed Bonus Issue with full powers to assent to any conditions, modifications,

variations, termination and/or amendments in any manner as may be required by the relevant authorities or deemed necessary by the Board and to deal with all matters relating thereto and to take all such steps and do all acts and things in any manner as the Board may deem necessary or expedient to implement, finalise and give full effect to the Proposed Bonus Issue."

The Chairman informed that the notice convening the Meeting had been dispatched to the shareholders together with the Circular to Shareholders on the Proposed Bonus Issue on 6 July 2021 and declared that the proposed Ordinary Resolution on the Proposed Bonus Issue in the Notice of Meeting of Members shall be taken as read.

Further, the Company had appointed Mercury Securities Sdn. Bhd. as the Principal Adviser for this exercise, and appointed Wee Chien & Partners as the Legal Adviser. The advisers were present to clarify on any matters, if required.

The Chairman briefed the shareholders on the rationale of the Proposed Bonus Issue. In this regard, the Board was of the view that the Proposed Bonus Issue was the most appropriate avenue of rewarding the existing shareholders for their continued support to the Company. The Proposed Bonus Issue would also enable the shareholders to have greater participation in the Company's equity in terms of the increased number of shares held whilst maintaining their respective percentage of shareholding in the Company without incurring any cost. The Proposed Bonus Issue would also enhance trading liquidity of the Company's shares on Bursa Malaysia Securities Berhad.

The Chairman informed that both Mr Krishnakumara-Reddi A/L Kesava-Reddi, the Chief Manufacturing Officer of the Company, and Ms Ng Su Yee, the Chief Technical Officer of the Company, who were also the shareholders of the Company and were virtually present at the Meeting, had offered themselves to be the proposer and seconder respectively for the Ordinary Resolution on the Proposed Bonus Issue.

The Chairman declared that voting on the Ordinary Resolution on the Proposed Bonus Issue shall be conducted on a poll.

#### **QUESTIONS AND ANSWERS ("Q&A")**

The Chairman then opened the Questions and Answers ("Q&A") session and invited shareholders to submit questions on the Proposed Bonus Issue. The Chairman invited the Group Managing Director ("GMD") to first take through the questions submitted by shareholders prior to this meeting and Management's responses for the same.

The GMD shared the questions submitted by individual shareholders prior to the Meeting. The questions and responses were projected on the screen during the meeting as follows:-

**Pre-MOM Questions from Shareholders:**

*Mr. Steward Tan Lai Heng*

**Question 1** : How will the vaccine business help to boost Duopharma Biotech's current earnings?

**Answer** : Being a new business in 2021, the covid-19 vaccine business will have some impact on earnings.

*Ms. Ng Mooi Cheng*

**Question 2** : Has Duopharma Biotech been appointed as a vaccine supplier? If yes, for which vaccine?

**Answer** : Yes, we are the product registration holder of Sinopharm's Covid 19 vaccine. It was approved in June 2021.

*Mr. Kow Lih Shi*

**Question 3 (a)** : The AGM Minutes which was published in early July was replaced with a new version in the middle of July. Is there any information that was deleted from the earlier version of the AGM minutes? Is there any information that was not disclosed to the shareholders?

**Answer** : The draft Minutes of AGM, without the Chairman's signature, was first published in June 2021, within one month from the AGM. The Minutes incorporated all key matters deliberated during the AGM.

The signed version of the Minutes of AGM was uploaded in July 2021 to replace the draft minutes that was published on the Company's website earlier. No changes/deletion of information compared to the earlier published draft Minutes of AGM.

All matters discussed at the 20th AGM were duly recorded and minuted.

**Question 3 (b)** : Will Duopharma Biotech be expanding the business by distributing and selling antigen for e.g. the Covid-19 test kits as well as immunity products and ethical drugs since the Company has the capability of producing some of these products?

**Answer** : We have started to sell both nasal swabs and saliva test kits in the last few months. At the same time, we have various consumer healthcare including vitamin C that helps with immunity development.



- Question 3 (c) : The Government's project spans a vast range of services including supplying and producing. Since pharmaceutical companies are experts in medical products, can Duopharma Biotech participate in this endeavour?
- Answer : Duopharma Biotech is currently the largest local manufacturer of generic medicines and we do participate actively in supplying to the Government.
- Question 3 (d) : Will the Company expand into producing food technology range?
- Answer : There are no plans at the moment to expand into the food technology range.
- Question 3 (e) : Producing ordinary food replacement technology?
- Answer : No plans at the moment.
- Question 3 (f) : How does KKM approve the Antigen Covid-19 test kits? Does Duopharma Biotech leverage the e-commerce platform to sell the kits and upload the test results as the Government have planned?
- Answer : Duopharma Biotech is currently selling both nasal swab and saliva-based RTK test kits. We are selling via various channels in the private sector.
- Question 3 (g) : Can Duopharma Biotech produce vaccines when vaccine supply shortage really happens?
- Answer : Duopharma Biotech has an inactivated vaccine fill and finishes facility. We are exploring the possibility of trading as well as possible manufacturing different vaccines.
- Question 3 (h) : Does Duopharma Biotech do R&D and clinical trials on human for Covid-19 or any other new viruses?
- Answer : We are exploring and sourcing technologies for various vaccines.
- Question 3 (i) : Since focus during the pandemic is on finding the solution to Covid-19, is new research in medicine taking the back seat?
- Answer : All other projects are moving in parallel. No issues with the progress of other projects.
- Question 3 (j) : During the pandemic years, is production affected by the reduction in the manpower?
- Answer : The demand for our products is still optimistic and so far we are still hiring manpower for various departments amidst the pandemic.

- Question 3 (k) : Can the Ministry of Health Malaysia continue to supply Vitamin C in Government clinics and hospitals to patients?
- Answer : This is not an issue as far as we know.
- Question 3 (l) : Can Duopharma Biotech manufacture specific medicines for patients for Covid-19 recovery?
- Answer : We supply various medicines for use in respiratory, immunity development supplements, and other relevant products.
- Question 3 (m) : Is there a shortage of raw materials and chemicals supply for production?
- Answer : We have managed the risk relating to the supply of raw and packaging materials as best as we could. However, there were some instances where certain raw and packaging materials supplies were affected. Other companies were also affected.
- Question 3 (n) : Will Duopharma Biotech be doing R&D on food science and marketing?
- Answer : No plans at the moment.
- Question 3 (o) : Will Duopharma be operating according to ESG and be an eco-friendly manufacturer?
- Answer : We strive to practise good governance, together with strong social citizenry and environmental stewardship, encompassing key aspects of environmental, social and governance ("ESG") principles to ensure our sustainability and good sustainable relationships with internal and external stakeholders.
- Question 3 (p) : Will Duopharma Biotech be able to export medical products to China?
- Answer : Duopharma Biotech has yet to export into China market as there has not been a strong opportunity for us to do so. We may explore this when the right opportunity and possible partnership arises.
- Question 3 (q) : Based on the potency of medical products manufactured in India, will Duopharma Biotech be using the formula from India?
- Answer : We do trade products from India and have various partners from India. All products are subject to local regulatory approvals prior to marketing authorisation.
- Question 3 (r) : Does Duopharma Biotech do OEM for Chinese medicines?

Answer : Currently, we do manufacture our in-house brands of products under the traditional and complementary medicine category. We are open to doing OEM if there is a business case.

Question 3 (s) : Malaysia last imposed iodine in salt in 2020. Does medical product manufacturing reduce the iodine % since daily food consumed by Malaysians already contain iodine in salt?

Answer : As of now, this does not apply to our products.

Question 3 (t) : Will year 2022's financial forecast and results be better than 2018 i.e. before the pandemic?

Answer : The outbreak of pandemics has posed many challenges to our business. Among others is the requirement to operate at reduced capacity. However, we are pleased to note that Duopharma Biotech's performance has been on an uptrend for FY 2019, 2020 & 2021.

Question 3 (u) : Will AI technology be applied to the Company's overall operation for saving time and having more output?

Answer : Duopharma Biotech has invested and migrated to a private cloud facility to facilitate the Group's digitization and automation process which are the main pillars in our IT strategy for operation and manufacturing processes of the Group.

For operation, implementation of a customer engagement portal and the automated internal process will reduce manual processes and increasing efficiency.

For manufacturing, we are implementing digitization and consolidation of manufacturing plant monitoring as well as improving support in our production line. Proactive monitoring in plant maintenance helps increase the efficiency in production output and improve our data integrity to enhance compliance.

Question 3 (v) : Will there be a new factory built?

Answer : A new factory will be built if there is a strong business case for it.

*Mr. Er Tsaur Jzi*

Question 4 : Certain clinics have started to let the public register for vaccination and received feedback that the vaccine choices will be Sinovac and Sinopharm.

When will Duopharma Biotech start to distribute Sinopharm in Malaysia?  
When is the target date for this vaccine to be approved by MOH? Will the vaccine come in bulk and the fill & finish done in Duopharma Biotech facilities?

**Answer :** We are the product registration holder of Sinopharm's Covid 19 vaccine. It was approved in June 2021. We will proceed to launch upon JKJAV approval on pricing to the private market. If there is demand and we reach economics of scale, we will explore local Fill and Finish opportunities for Malaysia and export.

*Mr. Heng Lih Khing*

**Question 5 (a) :** How much is the cost of Sinopharma vaccine to doctors and consumers?

**Answer :** We will proceed to launch upon JKJAV approval on pricing to the private market.

**Question 5 (b) :** When Sputnik V vaccine will be granted approval? Is there any change in the contract to supply to the Government?

**Answer :** Approval of the Sputnik vaccine hinges on its approval by WHO, we expect local approval to follow upon WHO approval. At the moment, no changes to the contract with Government.

**Question 5 (c) :** Any reason for the decline in share price?

**Answer :** Share price fluctuates based on various factors including market sentiments, we believe the share price will improve as long as we continue to perform well.

*Mr Stephen Lye Tuck Meng; Mr Loo Tuck Fatt; Ms Lim Chew Lin; Mr Kow Lih Shi; and Ms Chan Lai Yin*

**Question 6 :** Are there any e-vouchers or e-wallet for shareholders attending this meeting?

**Answer :** As stated in the administrative guide, we will not provide any voucher for this meeting of members.

The Chairman then invited the GMD to take through the questions that the Company had received as streamed by the Company's team of moderators, and Management's responses for the same.

*[Note: Questions minuted as per the raw questions received from shareholders/proxies and recorded in the Moderators' Link via TIIH Online Platform.]*

*Mr Chan Choon Heong*

- Question 1 : 1. what advantage & product does company have in the pipeline to continue growth?
2. what is the planning for the drawdown borrowing showing in company quarter report?
3. is it possible to explain what was the main reason that affect to the share price drop rapidly. Thanks

- Answer : 1. We have products in the biosimilars range, regenerative products, new generic offerings, including several biomaterials and biomedical products that are currently being developed in the pipeline. We are continuing to develop pipelines towards better offerings to the markets.
2. The drawdown of borrowings is mainly for the capital expenditure as per our Manufacturing Optimisation Strategy.

*Mr Tan Chin Chye*

- Question 2 : 1. Will Sinopharm become a SIGNIFICANT revenue stream for Duopharma going forward and will fill and finish be implemented?
2. How will the coming QR result be ? Any dividend to be announced as a reward to shareholders?
3. The share price of Duopharma has drop tremendously since last 3 weeks from RM3 to lowest RM2.35 since yesterday. Will there be any catalyst that will help it to reverse its course to a bullish trajectory in the immediate future?

- Answer 1. The COVIL0 vaccine from Sinopharm will be launched in due course and is forecasted to provide an additional revenue stream. Depending on MOH policy moving forward there may be additional revenues in future years. We are at the initial stages of discussions for fill and finish. Our focus is to now support the Government's National Immunisation Program.

- : 2. The quarterly results will be announced before the end of August.
- 3. The Board of Directors will deliberate on the dividend and announce it once decided.

*Mr Tan Chin Chye*

**Question 3** : PM announce an initiative called PERKUKUH yesterday which may affect PNB as a major shareholder of Duopharma. Do you see any SIGNIFICANT impact from this PERKUKUH? Please elaborate. Thank you

**Answer** : As of this moment, we have not received any directives from PNB. As a subsidiary of PNB, we will endeavour to support both PNB and Government's initiatives.

*Mr Teh Peng Tin*

**Question 4** : How much does the company spend on this virtual Egm ?

**Answer** : The expenditure for this virtual MOM is below RM100,000.

*Mr Kow Lih Shi*

**Question 5** : In pandemic how company in sustain profit earning maximum and also sourcing for gain income business, and also overcome competition among competitor in market Malaysia? How the board members ensure doing everyone efficiency work from home? Thanks.

**Answer** : We are managing the disruptions around the pandemic by ensuring that the SOPs by the Government are adhered to ensure that our staff are kept safe as much as possible. We are also monitoring closely at strengthening our cash flow, reducing spending where possible, and ensure that raw materials supply and other related logistical issues are manageable and de-risk these issues as much as possible. We have also explored various new offerings including RTK test kits both nasal swab and saliva-based and other new product verticals including digital healthcare.

Our HR has been doing active engagements and surveys with our staff to ensure that the staff are motivated, focused and adhering to the Work From Home etiquette and are disciplined in undertaking their work.

*Mr Ho Yueh Weng*

- Question 6 : 1. What is the real purpose of such bonus issue when at a lower number of shares base our company's share price keeps sliding lower and, besides, your major share holders have been net sellers at this period?
2. Why has our company still not been able to introduce a Covid-19 vaccine to the market? It seems our company is squandering this opportunity of helping vaccinate our population and at the same time improve our performance, but we are so slow, what is happening?

Answer : Sputnik V Vaccine is still pending approval by DCA and also WHO approval. We have received approval for the Sinopharm vaccine and is in the process of receiving Government approval to supply to the private market. This initiative is to support the National Immunisation Program.

*Mr Kow Lih Shi*

- Question 7 : The KKM recognise swab test and self test result upload kits, does company is distributor or partnership of manufacturing? It was the only for covid 19 kits? Any R&D for future to support medicine products? Or Support ER doctor or medicine emergency products?

Answer : We are the authorised distributor for Suguntech COVID-19 RTK Antigen swab test (country of origin - Korea) and Longsee COVID-19 Saliva Self-Test (country of origin, China).

Longsee 3 in 1 saliva test for healthcare professionals to test for COVID-19, Influenza A and Influenza B.

*Mr Pua Kok Chong*

- Question 8 : Dear member of boards - May I know when is the proposed ex date of proposed bonus issue? Thank you

Answer : The entitlement date of the bonus issue will be announced in due course.

*Mr Teh Peng Tin*

- Question 9 : May I know what is the rationale for this proposal of bonus issue ?

It will dilute the earning per share, and also the dividend. Please explain.

Answer : We believe the benefits of the proposed bonus issue outweighs the cons and will benefit the Company in the long run.

*Ms Chan Lai Yin*

Question 10 : Where can we get the sinopharm vaccine jab

Answer : Sinopharm's vaccine - COVIL0 will be supplied to private sector hospitals, clinics, states as well as collaboration with corporate clients.

*Mr Heng Lih Khing*

Question 11 : any conflict with Kanger sinopharm vaccine, as both from same product owner

Answer : We are the only authorized product registration holder for Sinopharm's vaccine in Malaysia as approved by the DCA.

*Mr Heng Lih Khing*

Question 12 : 1. what is the proactive measures for the sinopharm vaccine registered as no news published after registered on 15/7?

2. what is the proactive measure for sputnik vaccine registration ? as national vaccination has been largely carry out.

Answer : 1. We are focussing our efforts to get all related approvals to supply the product and have just received approval from the Government for the COVIL0 Sinopharm vaccine to supply to the private market.

2. Sputnik V Vaccine is still pending approval from DCA and WHO. We continue to engage and support local regulatory agency enquiries.

*Mr Thavarajan A/L Muthiah Pillai*

Question 13 : Will the company help KKM in doing FTTIS to combat the covid 19 pandemic.Tq

Answer : We are not currently undertaking the FTTIS work. Our work is to support the Government and the public to test via our test kits and to offer the COVID-19 vaccine to the private sector.

*Mr Lee Eng Shan*

Question 14 : How's the public sector tender market look like during the pandemic season? Any key growth drivers in coming months?

Answer : The public sector tenders market has seen strong growth in recent months.



- : We expect the results of some tenders to be announced soon, and are also submitting various other tenders/contracts to supply our products into the public sector.

*Mr Lee Eng Shan*

- Question 15 : Amongst the local generic drug manufacturers, what's Duopharma's value-add compare to the other players?

- Answer : We differentiate ourselves through our focus on specialty products (Insulin, Biosimilars), strategic investments in high tech companies both in the domestic and international markets and strategic partnerships. We also continuously work towards developing internal capabilities in new areas and grow into new markets internationally. We also focus on halal as a differentiator.

*Mr Leow Yuk Loong*

- Question 16 : Will there be any expansion of the company business? What is the capex will be allocate in the future?

- Answer : We have invested in rejuvenating our manufacturing assets, and will continue to improve our manufacturing and digital capabilities via our Manufacturing Optimisation Plan. We are also looking forward to potential expansions in the near future.

*Mr Sivanesan A/L K Sivalingam*

- Question 17 : Noticed EPF buying stake in the company. Are they the major shareholder now?

- Answer : EPF is an existing substantial shareholder while our largest shareholder remains to be PNB.

*Mr Ooi Cheng Kooi*

- Question 18 : Do the company have the test kit to test the effectiveness of the covid vaccine after injection.?

- Answer : The test kit to test for effectiveness is often done by doing a Neutralizing Antibody Test. We will launch Neutralizing Antibody Tests in the near future.

We are the authorized distributor via collaboration with Korean and Chinese companies for the two types of RTK kits. The product has been launched in the market.

*Ms Lim Siew Leng*

Question 19 : Why is the to substantial shareholder kept on disposing their shares?

Answer : All shareholders are able to trade in open market.

We have no visibility to the trading decisions of our shareholders.

However, as per Bursa Malaysia's Main Market Listing Requirements, dealings by substantial shareholders must be announced by the Company upon receiving notice of such dealing.

*Mr Ooi Cheng Kooi*

Question 20 : can the speech volume be increase?? is very soft even i have tune to the max.

Answer : The volume is set based on optimum settings.

*Ms Ong Julain*

Question 21 : How is the welfare of the employees especially those in the factories. Have they been vaccinated?

Answer : HR has organized various activities for employees to ensure their well-being are taken care of. More than 80% of our staff have already received the first dose of vaccine and waiting for the second dose.

*Mr Ooi Cheng Kooi*

Question 22 : there are many reports that ivermectin also is effective to treat covid disease, how do company view this?

Answer : This molecule ivermectin is not an approved treatment for C19 currently. Registered for animal use. Off label use for Ivermectin needs to go through application for approval with the Ministry.

*Mr Lee Eng Shan*

Question 23 : How would you describe the co.'s current raw material supply environment? Any cause for concern?

Answer : We are monitoring the situation as far as raw and packaging materials closely since the pandemic started. There have been minor disruptions, and we and the MOH are continuing to monitor closely so as not to have a significant impact to supply to our customers.

*Mr Phuah Kean Ming*

Question 24 : In what currency is the cost of vaccines settled, (Expected impact of foreign exchange?) How did the company cope? Thks

Answer : Cost of the vaccine is primarily in USD. if there is a need, we will hedge the forex exposure.

*Mr Liew Chee Seng*

Question 25 : How much is the cost of of sinopharm per dose?

Answer : We do not disclose the cost of our products.

*Ms Lim Siew Leng*

Question 26 : spending RM100K for virtual general meeting is way too much.

Answer : The expenditure includes expenses for the Proposed Bonus Issue.

*Mr Eng Beng Weng*

Question 27 : As all the covid-19 vaccines are 'new', don't you think all the people in the whole world are being use as guinea pigs to test the vaccines? That is why you see a lot of side effects and death in humans. What is your comments...

Answer : Given the pandemic, vaccines are seen to be an option to boost immunity against the virus. We will only be able to comment further post completion of all the Phase III trials.

Based on the listing of questions by the Company's team of moderators, there were no more incoming questions and further questions, if any, would be responded by the Company on the Company's corporate website. The Chairman then drew the Questions and Answers Session to a close.

The list of all questions received (including those that had not been answered during the Questions and Answers Session) and the answers thereto was appended as Appendix III of this Minutes of Meeting.

Upon conclusion of the Questions and Answers Session, Mr. Chris Lai from Mercury Securities Sdn. Bhd., the Principal Adviser for the Proposed Bonus Issue, was invited by the Chairman to give an overview of the Proposed Bonus Issue to the shareholders. Mr. Chris Lai proceeded to present a brief overview of the Proposed Bonus Issue including to highlight the rationale for the Proposed Bonus Issue.

## **AGENDA NO. 2**

**To transact any other business of which due notice shall have been received.**

The Chairman informed that the last Agenda item was to transact any other ordinary business for which due notice has been given. The Company Secretary confirmed that the Company had not received any notice for transaction of other ordinary business at the Meeting.

## **CONDUCT OF POLL VOTING**

As there was no other business transacted at the Meeting, the Chairman allowed another 10 minutes before declaring the end of the online voting session.

At 10.35 a.m., the Chairman declared that the voting session for the MOM of Duopharma Biotech Berhad through online voting had ended. The Chairman informed that:-

- (a) the Poll Administrator would compile and hand over the poll results to the scrutineers for validation; and
- (b) that the poll results were targeted to be announced at about 10.55 a.m., which was about 20 minutes from the declaration of end of voting session.

While waiting for the final results from the scrutineers, the Company's corporate video was screened.

## **OUTCOME OF THE MOM - POLL RESULTS**

At 10.55 a.m., Tan Sri Chairman called the MOM to order for the declaration of the results. The polling result which had been verified by the Scrutineers, Scrutineer Solutions Sdn Bhd, was presented on the screen. The poll results were as follows:

Resolution	Vote For		Vote Against		Total Votes	
	No. of Units	%	No. of Units	%	No. of Units	%
Ordinary Resolution	480,905,928	99.9913	41,786	0.0087	480,947,714	100

The Chairman declared that the Ordinary Resolution as contained in the Notice of the Meeting of Members of Duopharma Biotech Berhad had been carried.

## **CLOSE OF MEETING**

Before closing the Meeting, the Chairman encouraged the shareholders and proxies to give their feedback on the Virtual MOM by participating in the Post-Virtual MOM Survey to help the Company improve its stakeholder engagement process. The Post-Virtual MOM Survey was made available in a weblink and QR code shown on the screen.

The Chairman informed that the business for the Meeting of Members had been concluded and thanked the shareholders for their interest in the Company and for their attendance. The Chairman then declared the fully virtual Meeting of Members of Duopharma Biotech Berhad closed at 10.56 a.m..

*Note: The full minutes of the Meeting of Members of Duopharma Biotech Berhad is available for Members' inspection without charge at the Company's registered office pursuant to Section 48 of the Companies Act 2016.*


**PREPARED BY:-**



IBRAHIM HUSSIN SALLEH  
Company Secretary

Date: 07 SEP 2021


**VERIFIED BY:-**



LEONARD ARIFF BIN ABDUL SHATAR  
Group Managing Director

Date: 07 SEP 2021

**APPROVED BY:-**



TAN SRI DATIN PADUKA SITI SA'DIAH BINTI SH BAKIR  
Chairman

Date: 07 SEP 2021

### Annexure III

**Answered Questions Received from the Shareholders or their Proxies/  
Corporate Representatives during the Meeting of Members held on Friday,  
13 August 2021 at 9.00 a.m. via TIH Online Platform at <https://tiih.online>**

No.	Shareholders /Proxy	Raw Questions from Shareholder/ Proxy (Question documented as per recorded in the Moderators' Link via TIH Online Platform)	Reference made to the Minutes of the MOM of the Company	Answer(s)
1.	Mr Chew Choy @ Chow Chin Hai	please give e vouchers thank you.	Answer to Question 6 [Pre-MOM questions from shareholders] on Page 11	As stated in the administrative guide, we will not provide any voucher for this meeting of members.
2.	Mr Fong Sek Aun	I wish to ask what is the status of the deal to supply Spunik V vaccine to Government of Malaysia.	Answer to Question 5 (b) [Pre-MOM questions from Shareholders] on Page 11	Approval of the Sputnik vaccine hinges on its approval by WHO, we expect local approval to follow upon WHO approval. At the moment, no changes to the contract with Government.
3.	Mr Fong Sek Aun	My another question is with regards to the deal Duopharma sister company is engaged to supply Sinopharm vaccine to Government of Malaysia. May I know the ongoing progress and status of that deal?	Answer to Question 4 [Pre-MOM questions from Shareholders] on Page 10	We are the product registration holder of Sinopharm's Covid 19 vaccine. It was approved in June 2021. We will proceed to launch upon JKJAV approval on pricing to the private market. If there is demand and we reach economics of scale, we will explore local Fill and Finish opportunities for Malaysia and export.
4.	Mr Chan Choon Heong	1. what advantage & product does company hve in the pipeline to continue growth?  2. what is the planning for the drawdown borrowing showing in company quarter report?	-  -	1. We have products in the biosimilars range, regenerative products, new generic offerings, including several biomaterials and biomedical products that are currently being developed in the pipeline. We are continuing to develop pipelines towards better offerings to the markets.  2. The drawdown of borrowings is mainly for the capital expenditure as per our Manufacturing Optimisation Strategy.

		3. is it possible to explain what was the main reason that affect to the share price drop rapidly. Thanks	Answer to Question 5 (c) [Pre-MOM questions from Shareholders] on Page 11	3. Share price fluctuates based on various factors including market sentiments, we believe the share price will improve as long as we continue to perform well.
5.	Mr Lau Chuan Hooi	Will the Board consider giving door gift, such as e-voucher or e-wallet for those that have participated in this AGM ?	-	Please refer to the response to Question No. 1 above.
6.	Mr Tan Chin Chye	<p>1. Will Sinopharm become a SIGNIFICANT revenue stream for Duopharma going forward and will fill and finish be implemented?</p> <p>2. How will the coming QR result be ? Any dividend to be announced as a reward to shareholders?</p> <p>3. The share price of Duopharma has drop tremendously since last 3 weeks from RM3 to lowest RM2.35 since yesterday. Will there be any catalyst that will help it to reverse its course to a bullish trajectory in the immediate future?</p>	-	<p>1. The COVIL vaccine from Sinopharm will be launched in due course and is forecasted to provide an additional revenue stream. Depending on MOH policy moving forward there may be additional revenues in future years. We are at the initial stages of discussions for fill and finish. Our focus is to now support the Government's National Immunisation Program.</p> <p>2. The quarterly results will be announced before the end of August.</p> <p>3. The Board of Directors will deliberate on dividend and announce it once decided.</p>
7.	Mr Kow Lih Shi	In pandemic how company in sustain profit earning maximum and also sourcing for gain income business, and also overcome competition among competitor in market Malaysia? How the board members ensure doing everyone efficiency work from home? Thanks.	-	1. We are managing the disruptions around the pandemic by ensuring that the SOPs by the Government are adhered to to ensure that our staff are kept safe as much as possible. We are also monitoring closely at strengthening our cash flow, reducing spending where possible, and ensure that raw materials supply and other related logistical issues are manageable and de-risk these issues as much as possible. We have also explored various new

				offerings including RTK test kits both nasal swab and saliva-based, and other new product verticals including digital healthcare.  2. Our HR has been doing active engagements and surveys with our staff to ensure that the staff are motivated, focused and adhering to the Work From Home etiquette and are disciplined in undertaking their work.
8.	Mr Leong Fook Sen @ Francis Leong	Mr Chairman. Kindly provide e vouchers to shareholders who attend RPV. TOUCH GO VALUE 100.00. TQVM.	-	Please refer to the response to Question No. 1 above.
9.	Mr Chan Choon Heong	any update news for the vaccine fill & finish? v-spunik vaccine is it still running?	-	Please refer to the response to Question No. 2 above.
10.	Mr Lau Ali @ Lau Chuan Teng	Please consider giving e-voucher to participating shareholders in view of the amount of hassle and cost for registration to attend the meeting, Thank you.	-	Please refer to the response to Question No. 1 above.
11.	Mr Tan Chin Chye	PM announce an initiative called PERKUKUH yesterday which may affect PNB as a major shareholder of Duopharma. Do you see any SIGNIFICANT impact from this PERKUKUH? Please elaborate. Thank you	-	As of this moment, we have not received any directives from PNB. As a subsidiary of PNB, we will endeavour to support both PNB and Government's initiatives.
12.	Mr Nge Ei @ Lee Leong Chai	Would like to know why the share price keep falling the past few days despite the announcement of the bonus shares. And what is the rationale of having the bonus shares despite the downward market trend. thank you	Answer to Question 5 (c) [Pre-MOM questions from Shareholders on Page 11	Share price fluctuates based on various factors including market sentiments. We believe our share price will improve as long as we continue to perform well.  The proposed issuance of bonus shares will among others enhance trading liquidity and increase the marketability of our shares.



13.	<i>Mr Lee Chong Sing</i>	Good morning Mr. Chairman and board of directors. I wish to request for E-wallet as a token of appreciation to shareholders who attending this mom meeting. Tqvm in advance for your kind consideration.	-	Please refer to the response to Question No. 1 above.
14.	<i>Mr Stephen Lye Tuck Meng</i>	Dear BOD - Kindly give us some e-vouchers, food vouchers or e-wallet (no discount vouchers please) for being loyal shareholders and attending this meeting. Times are bad now. Please be considerate to us shareholders during these trying times. TQ	-	Please refer to the response to Question No. 1 above.
15.	<i>Mr Kow Lih Shi</i>	The KKM recognise swet test and self test result upload kits, does company is distributor or partnership of manufacturing? It was the only for covid 19 kits? Any R&D for future to support medicine products? Or Support ER doctor or medicine emergency products?	-	We are the authorized distributor for Suguntech COVID-19 RTK Antigen swab test (country of origin - Korea) and Longsee COVID-19 Saliva Self-Test (country of origin, China).  Longsee 3 in 1 saliva test for healthcare professionals to test for COVID-19, Influenza A and Influenza B.
16.	<i>Mr Khoo Yew Yik</i>	Kindly give e-vouchers for us who attending the MoM too.	-	Please refer to the response to Question No. 1 above.
17.	<i>Ms Chow Lee Ming</i>	Please give vouchers thank you.	-	Please refer to the response to Question No. 1 above.
18.	<i>Ms Chan Lai Yi</i>	Hope the board will give us e vouchers to redeem your proiducts	-	Please refer to the response to Question No. 1 above.
19.	<i>Ms Goh Su Looi @ Goh Pek Leng</i>	Please provide a goorgift for those shareholders attending.thks	-	Please refer to the response to Question No. 1 above.
20.	<i>Ms Lau Ite Lian</i>	recently share price drop is it booz of your company cannot get the vaccination	-	Please refer to the response to Question No. 12 above.

		program from government?		
21.	Mr Kok Sak Lin	Mr. Chairman, in this difficult Pandemic period, please give Ewallet credits (e.g. Touch&Go) for us loyal minority shareholders voting today. Thank you.	-	Please refer to the response to Question No. 1 above.
22.	Mr Teh Peng Tin	How much does the company spend on this virtual Egm ?	-	The expenditure for this virtual MOM is below RM100,000.
23.	Mr Ho Yueh Weng	<p>1. What is the real purpose of such bonus issue when at a lower number of shares base our company's share price keeps sliding lower and, besides, your major share holders have been net sellers at this period?</p> <p>2. Why has our company still not been able to introduce a Covid-19 vaccine to the market? It seems our company is squandering this opportunity of helping vaccinate our population and at the same time improve our performance, but we are so slow, what is happening?</p>	<p>Chairman's briefing on Agenda No. 1 (Ordinary Resolution) on Page 6.</p> <p>-</p>	<p>1. The Board is of the view that the Proposed Bonus Issue is the most appropriate avenue of rewarding the existing shareholders for their continued support to the Company.</p> <p>The Proposed Bonus Issue will also enable our shareholders to have greater participation in the Company's equity in terms of the increased number of shares held whilst maintaining their respective percentage of shareholding in our Company without incurring any cost and without diluting their total investment value. The Proposed Bonus Issue will also enhance trading liquidity of the Company's shares on Bursa Malaysia Securities Berhad.</p> <p>2. Sputnik V Vaccine is still pending approvals from Malaysia's Drug Control Authority ("DCA") and WHO. However, we were granted approval by DCA for the Sinopharm vaccine and we are in the midst of obtaining Government approval to supply to the private market. This initiative is also to support the Government's National Immunisation Program.</p>
24.	Ms Lum Pek Kam	Mr. Chairman, please give Ewallet credits (e.g. Touch&Go) for us loyal minority shareholders voting today. Thank you.	-	Please refer to the response to Question No. 1 above.

25.	Mr Teh Peng Tin	<p>May I know what is the rationale for this proposal of bonus issue ?</p> <p>It will dilute the earning per share, and also the dividend. Please explain.</p>	-	<p>The Board is of the view that the Proposed Bonus Issue is the most appropriate avenue of rewarding the existing shareholders for their continued support to the Company.</p> <p>The Proposed Bonus Issue will also enable our shareholders to have greater participation in the Company's equity in terms of the increased number of shares held whilst maintaining their respective percentage of shareholding in our Company without incurring any cost and without diluting their total investment value. The Proposed Bonus Issue will also enhance trading liquidity of the Company's shares on Bursa Malaysia Securities Berhad.</p> <p>We believe the benefits of the proposed bonus issue outweighs the cons and will benefit the Company in the long run.</p>
26.	Ms Kong Fon Yeen	Any door gifts?	-	Please refer to the response to Question No. 1 above.
27.	Ms Chong Lim Fah	CAN THE CHAIRMAN KINDLY CONSIDER GIVING TOUCH AND GO EVOUCHERS TO THE SHAREHOLDERS WHO ATTEND THIS EGM. THANK YOU	-	Please refer to the response to Question No. 1 above.
28.	Mr Chan Chee Hong	<p>We would appreciate it if the Board can regard it fit to provide some form of e-vouchers or gift for shareholders who attended this meeting. Thanks</p> <p>THE SHAREHOLDERS WHO ATTEND THIS EGM. THANK YOU</p>	-	Please refer to the response to Question No. 1 above.
29.	Ms Chan Ngun Fong	Please give all participants of this virtual meeting some vouchers, evouchers or ewallet top ups to brighten up our day during this Covid-19 pandemic. Thank you.	-	Please refer to the response to Question No. 1 above.

30.	<i>Ms Lum Peck Wan</i>	Dear Chairman & Board of Directors, Truly hope you can reward us who took time & effort to attend this MOM with some E-wallet or E-Vouchers to help us during this trying times. Thank you	-	Please refer to the response to Question No. 1 above.
31.	<i>Mr Lim Leng Yaw</i>	Any door gifts?	-	Please refer to the response to Question No. 1 above.
32.	<i>Mr Teh Peng Tin</i>	I'm a long time and loyal shareholder of the company, I would like to request that the company reward shareholder with e-voucher to redeem the company products as a token of appreciation for shareholder who take time and interest to participate in this RPV .. especially during this current difficult period of Covid 19 pandemic. Thank you	-	Please refer to the response to Question No. 1 above.
33.	<i>Enik Mohd Tahir Bin Mauluti</i>	Although The Company's circular to shareholders mentioned that, there will be NO DOOR GIFT or FOOD VOUCHERS to be distributed. I as a small shareholder would like to request The Company to do so. Our company will indirectly help The Country's economy growth just spending a little money. One stone kill 3 birds, Hope The Broad of Director will consider it. TQ	-	Please refer to the response to Question No. 1 above.
34.	<i>Ms Lim Siew Leng</i>	Why is the to substantial shareholder kept on disposing their shares?	-	<p>All shareholders are able to trade in the open market.</p> <p>We have no visibility to the trading decisions of our shareholders.</p> <p>However, as per Bursa Malaysia's Main Market Listing Requirements, dealings by substantial shareholders must</p>

				be announced by the Company upon receiving notice of such dealings.
35.	Ms Lee Suan Bee	Can the company give us e- wallet as a token of appreciation who has taken time and interest to participate in today's RPV.	-	Please refer to the response to Question No. 1 above.
36.	Mr Lim Pin Yeong	Can shareholder have some goodies for participating in this EGM.? Missed the goodies bag of the physical AGM. Sime Plantation and MSM couriered the goodies bag to shareholders.	-	Please refer to the response to Question No. 1 above.
37.	Ms Shirley Tan	Please give us some vouchers, evouchers or ewallet top ups as token of appreciation for attending this meeting. Thank you for your kind consideration.	-	Please refer to the response to Question No. 1 above.
38.	Mr Pua Kok Chong	Dear member of boards - May I know when is the proposed ex date of proposed bonus issue? Thank you	-	The entitlement date of the bonus issue will be announced in due course.
39.	Mr Lee Ah Chai @ Lee Tien Sing	May I request for a token of appreciation for attending this meeting Thank you	-	Please refer to the response to Question No. 1 above.
40.	Mr Hew Soon Hin	Any door gift this morning	-	Please refer to the response to Question No. 1 above.
41.	Mr Ronald Danker	1. Any door gifts for the shareholders?	-	Please refer to the response to Question No. 1 above.
42.	Mr Heng Lih Khing	2. what is the proactive measures for the sinopharm vaccine registered ? as no news published after registered on 15/7 3. what is the proactive measure for sputnik vaccine registration ? as national vaccination has	-	1. We are focussing our efforts to get all related approvals to supply the product and have just received approval from the Government for the COVIL0 Sinopharm vaccine to supply to the private market. 2. Sputnik V Vaccine is still pending approval from DCA and WHO. We continue to engage and support local regulatory agency enquiries.

		been largely carry out		
43.	Ms Chan Lai Yin	Where can we get the sinopharm vaccine jab	-	Sinopharm's vaccine - COVIL0 will be supplied to private sector hospitals, clinics, states as well as collaboration with corporate clients.
44.	Ms Catherine Kok Yin Ling	Mdm Chairperson, thank you for the Bonus Issue but minority shareholders would appreciate a token of appreciation for attending the virtual EGM. The cost is negligible to the company. Thank you.	-	Please refer to the response to Question No. 1 above.
45.	Mr Heng Lih Khing	any conflict with Kanger sinopharm vaccine, as both from same product owner	-	We are the only authorised product registration holder for Sinopharm's vaccine in Malaysia as approved by the DCA.
46.	Ms See Yoot Wah	Appreciate you reconsider give Us evoucher to get some pharmaceutical products to tide over Covid storm. God bless	-	Please refer to the response to Question No. 1 above.
47.	Mr Thavarajan A/L Muthiah Pillai	Will the company help KKM in doing FTTIS to combat the covid 19bpandemic.Tq	-	We are not currently undertaking the FTTIS work. Our work is to support the Government and the public to test via our test kits and to offer the COVID-19 vaccine to the private sector.
48.	Mr Lee Eng Shan	How's the public sector tender market look like during the pandemic season? Any key growth drivers in coming months?	-	The public sector tender market has seen strong growth in recent months.  We expect the results of some tenders to be announced soon, and are also submitting various other tenders/contracts to supply our products into the public sector.
49.	Mr Tan Teng Chee	Appreciate you reconsider for us to get your many products to tide over covid storm for us senior citizens .Thank you.God bless	-	Please refer to the response to Question No. 1 above.
50.	Mr Lee Eng Shan	Amongst the local generic drug manufacturers, what's Duopharma's	-	We differentiate ourselves through our focus on speciality products (Insulin, Biosimilars), strategic investments in high

		value-add compare to the other players?		tech companies both in the domestic and international markets and strategic partnerships. We also continuously work towards developing internal capabilities in new areas and grow into new markets internationally. We also focus on halal as a differentiator.
51.	Mr Leow Yuk Loong	Will there be any expansion of the company business? What is the capex will be allocate in the future?	-	We have invested in rejuvenating our manufacturing assets and will continue to improve our manufacturing and digital capabilities via our Manufacturing Optimisation Plan. We are also looking forward to potential expansions in the near future.
52.	Mr Ho Yueh Weng	This bonus issue, according to our company's/Chairman's statement that it "benefits shareholders", is erroneous and misleading. Bonus issues are entirely neutral, but will be detrimental to shareholders due to dilution of share base, eps, dividends/share that results in lower adjusted pricing in the market. So where exactly is shareholders benefits coming from if all things remain the same, please elaborate?	-	The Increased share capital will allow greater participation in the trading of our shares without affecting their percentage of shareholding.  The improved liquidity will increase the marketability of our shares.  We believe it will benefit the shareholders and our Company as a whole in the long run.
53.	Mr Lee Eng Shan	Is Duopharma looking into Pharmanlaga's distribution business when its concession expires?	-	We are open to exploring any new business including the logistics and distribution services to MOH if the business adds value to Duopharma.
54.	Mr Sivanesan A/L K Sivalingam	Noticed EPF buying stake in the company. Are they the major shareholder now?	-	EPF is an existing substantial shareholder while PNB remains as our largest shareholder.
55.	Mr Ooi Cheng Kooi	Do the company have the test kit to test the effectiveness of the covid vaccine after injection.?	-	The test kit to test for effectiveness is often done by doing a Neutralizing Antibody Test. We will launch Neutralizing Antibody Tests in the near future.

				We are the authorized distributor via collaboration with Korean and Chinese companies for the two types of RTK kits. The product has been launched in the market.
56.	Mr Ooi Cheng Kooi	there are many reports that ivermectin also is effective to treat covid disease, how do company view this?	-	This molecule ivermectin is not an approved treatment for C19 currently. Registered for animal use. Off label use for Ivermectin needs to go through an application for approval with the Ministry
57.	Ms Ong Julain	How is the welfare of the employees especially those in the factories. Have they been vaccinated?	-	HR has organized various activities for employees to ensure their well-being are taken care of. More than 80% of our staff have already received the first dose of vaccine and waiting for the second dose.
58.	Mr Lee Eng Shan	How would you describe the co.'s current raw material supply environment? Any cause for concern?	-	We are monitoring the situation as far as raw and packaging materials closely since the pandemic started. There have been minor disruptions, and we and the MOH are continuing to monitor closely so as not to have a significant impact to supply to our customers.
59.	Mr Phuah Kean Ming	In what currency is the cost of vaccines settled; (Expected impact of foreign exchange?) How did the company cope? Thks	-	The cost of the vaccine is primarily in USD. If there is a need, we will hedge the forex exposure.
60.	Mr Ooi Cheng Kooi	can the speech volume be increase?? is very soft even i have tune to the max.	-	The volume is set based on optimum settings.
61.	Ms Lim Siew Leng	spending RM100K for virtual general meeting is way too much.	-	The expenditure includes expenses for the Proposed Bonus Issue.
62.	Mr Teh Peng Tin	May I know why my question is answer ? Please explain  <u>Earlier question received on e-voucher</u>	-	Please refer to the response to Question No. 1 above.
63.	Mr Lee Hoe Choon	I understand that Kanger International also imported Sinopharm vaccine, has it been replaced by our company?	-	Please refer to the response to Question No. 45 above.



		This is in reference to their collaborative agreement with Sinopharm in Sept 2020.		
64.	Mr Ooi Cheng Kooi	can the meeting organising chairman re-consider give vouchers to attending shareholders as the attending Directors also enjoy attending allowances.??	-	Please refer to the response to Question No. 1 above.
65.	Ms Siew Yoke Keng	Can we get samples of the test kits which will come in very useful in these times. Thanks.	-	At the moment, stocks available are to fulfill the market demand by clinics, pharmacies and corporate clients.
66.	Mr Liew Chee Seng	How much is the cost of of sinopharm per dose?	-	We do not disclose the cost of our products.
67.	Mr Lim Jit Thin	You mentioned the proposed shares bonus would make the company shares more affordable to buy but the share prices had gone down about 30% in recent months, please explain	-	Please refer to the response to Question No. 12 above.
68.	Mr Lum Choong Ying	BOD kindly consider to reward shareholders with Duopharma e-products. Thanks	-	Please refer to the response to Question No. 1 above.
69.	Mr Eng Beng Weng	As all the covid-19 vaccines are 'new', don't you think all the people in the whole world are being use as guinea pigs to test the vaccines? That is why you see a lot of side effects and death in humans. What is your comments...	-	Given the pandemic, vaccines are seen to be an option to boost immunity against the virus. We will only be able to comment further post completion of all the Phase III trials.
70.	Mr Lai Kim Loong	How about production of Ivermectin?	-	Please refer to the response to Question No. 56 above.
71.	Ms Lau Ite Lian	Any efforts that DPHARMA made for ESG lately?	Answer to Question 3 (c) [Pre-MOM questions] on Page 9	We strive to practise good governance, together with strong social citizenry and environmental stewardship, encompassing key aspects of environmental, social and governance ("ESG") principles to ensure our sustainability and good sustainable relationships

				with internal and external stakeholders.
72.	Mr Eng Beng Weng	Ivermectin had been used in many countries, eg. India, Peru, Philippines, Africa, Indonesia, etc. and proven successful in reducing the covid-19 without side effects. Why is it not being used in Malaysia? Is it because there is no profit to be made as it is very cheap?	-	Please refer to the response to Question No. 56 above.
73.	Ms Chan Lai Yin	will Duopharma sell ivermectin because Merck used to sell them in African countries widely and was also a popular medicine	-	Please refer to the response to Question No. 56 above.
74.	Ms Tan Siew Hoon	Hi i came in late, do the company selling the ivermectin medicine?	-	Please refer to the response to Question No. 56 above.
75.	Mr Chia Cheong Chin @ Chia Yew Chin	I would like to know whether loyal shareholders would be rewarded with e vouchers for attending this meeting. Thank you	-	Please refer to the response to Question No. 1 above.
76.	Mr Tan Kheng Yent	Any e-vouher	-	Please refer to the response to Question No. 1 above.

**Unanswered Questions Received from the Shareholders or their Proxies/  
Corporate Representatives during the Meeting of Members held on Friday,  
13 August 2021 at 9.00 a.m. via TIH Online Platform at <https://tihih.online>**

No.	Shareholders /Proxy	Raw Questions from Shareholder/ Proxy (Question documented as per recorded in the Moderators' Link via TIH Online Platform)	Reference made to the Minutes of the MOM of the Company	Answer(s)
1.	Mr Lee Eng Shan	Israel is said to have invented a cure for covid days ago. Any comments? Should we look into it?	-	Duopharma is constantly on the lookout for new molecules and products. There have been various claims of cure, treatments etc. for COVID-19. Various factors need to be carefully assessed including technical aspects of the product, commercial viability and legal requirements.

2.	Mr Eng Beng Weng	Recently there are people going to do antibody test after finishing their 2 doses and came back with negative result, meaning no antibody. Why is it that way since they had already taken both doses? Is the vaccines ineffective?	-	Absence of antibodies does not mean vaccine is not effective. The negative result could be due to many reasons. Sometimes it could be that testing was done too early or too late, then you will not have any antibodies as antibodies will be in the system only when you are exposed to the virus. Another possibility is no immune response by the individual to the vaccine.
3.	Mr Lee Tuck Feong	How transparent and accountable are you by getting this sole distributorship of this vaccine? are shareholders rewarded?	-	As a GLC and a listed entity, we publish as much information as we are required to. Shareholders will be rewarded through annual dividends if the Company performs well, is solvent and there are reasonable profits available for distribution.
4.	Mr Lee Tuck Feong	bonus shares only dilution not appreciation of value.	Chairman's Speech on Agenda No. 1 (Ordinary Resolution) on Page 6  -	<p>The Board is of the view that the Proposed Bonus Issue is the most appropriate avenue of rewarding the existing shareholders for their continued support to the Company.</p> <p>The Proposed Bonus Issue will also enable our shareholders to have greater participation in the Company's equity in terms of the increased number of shares held whilst maintaining their respective percentage of shareholding in our Company without incurring any cost and without diluting their total investment value. The Proposed Bonus Issue will also enhance trading liquidity of the Company's shares on Bursa Malaysia Securities Berhad.</p> <p>We believe the benefits of the proposed bonus issue outweighs the cons and will benefit the Company in the long run.</p>

Shareholder/ Proxy	Comments from Shareholder
Mr Khoo Yew Yik	Thank you Encik Leonard Ariff on detailed explanation and also questions from Mr Kow.
Mr Lim Liew Leng	Thank you, Encik Leonard.